Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15624129 | 0.94 | SPHK1 (0.41) | SPHK1ACEALDH1A1LMNA | |
| SCHEMBL15624144 | 0.94 | SPHK1 (0.41) | SPHK1ACEALDH1A1LMNA | |
| SCHEMBL15624153 | 0.93 | ACE (0.38) | SPHK1ACEALDH1A1GAADPP4 | |
| SCHEMBL29982946 | 0.92 | ACE (0.40) | SPHK1ACEALDH1A1GAADPP4 | |
| SCHEMBL15624158 | 0.90 | ACE (0.40) | ACELMNARAB9ASMN1; SMN2PKM | |
| SCHEMBL29982293 | 0.89 | ACE (0.42) | ACE | |
| SCHEMBL5496756 | 0.86 | SPHK1 (0.43) | SPHK1ACEFKBP1A | |
| SCHEMBL6875002 | 0.86 | SPHK1 (0.43) | SPHK1ACEFKBP1A | |
| SCHEMBL5496759 | 0.86 | SPHK1 (0.43) | SPHK1ACEFKBP1A | |
| SCHEMBL19944614 | 0.86 | DPP4 (0.44) | ACEDPP4RAB9AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1458680-A1 | PRODRUGS TO D-PROLINES | F. Hoffmann-La Roche AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
| WO-2003051836-A1 | PRODRUGS TO D-PROLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | SPHK1 1147/4885ACE 330/4885ALDH1A1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.